Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with Stage III or IV non-small cell lung cancer (a type of lung cancer) that has spread or is advanced
- You are currently being treated with one of these specific immunotherapy drugs approved by the FDA: pembrolizumab, atezolizumab, nivolumab, or cemiplimab — and have been on it for at least 12 weeks
- Your doctor has seen signs that your cancer may be growing or changing on scans, but does not feel you need to switch treatments immediately — at least one area of cancer must appear to be growing
- You are well enough to carry out daily activities, with only mild limitations at most (confirm with trial site)
- Your doctor expects you to live for at least 6 months
- Your blood cell counts and organ function (blood, kidneys, and liver) meet certain minimum levels based on lab tests (confirm with trial site for exact values)
- You are able to swallow and take pills by mouth
- You are willing and able to attend all required appointments and follow the study plan for its full duration
Who may not be able to join:
- You are currently enrolled in another clinical trial that involves treatment
- You are currently taking blood-thinning medications, such as warfarin, heparin, rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), or similar drugs
- You have received or are planning to receive a drug called bevacizumab within 6 weeks of starting the study
- Your blood clotting levels are outside the acceptable range based on a lab test (confirm with trial site)
- You cannot take anti-inflammatory pain medications (NSAIDs) — for example, if you take daily aspirin for heart or stroke prevention, have stomach ulcers, a known bleeding disorder, a known allergy to NSAIDs, advanced kidney disease, uncontrolled high blood pressure, or a known seizure disorder
- You are a woman who could become pregnant and are unwilling or unable to use two forms of contraception as described in the study
- You have another serious illness that is not well controlled
- You have a history of another cancer (some exceptions may apply — confirm with trial site)
- You have an active immune system disorder, or an active infection such as tuberculosis, hepatitis B, or hepatitis C
- You have taken immune-suppressing medications within the past 14 days (some exceptions may apply — confirm with trial site)
- You have received a live vaccine within the past 30 days before starting the study
- The study doctor feels, for any reason, that the trial would not be appropriate for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jennifer W Carlisle, Emory University Hospital/Winship Cancer Institute
Phone: 404-778-5087
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical benefit rate (CBR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.